论文部分内容阅读
从八十年代Ｒｏｓｅｎｂｅｒｇ等[1] 观察到在患非免疫系统肿瘤的动物中给予重组白细胞介素 - 2 (ｒＩＬ -2 ) ,动物的淋巴细胞可以调节肿瘤的消退和转移以来 ,细胞免疫治疗的临床领域就迅速扩展开来 ,人们先后研究了淋巴因子激活的杀伤 (ＬＡＫ )细胞[2 ] ,肿瘤浸润淋巴 (ＴＩ
From the 1980s Rosenberg et al. [1] observed that administration of recombinant interleukin-2 (rIL-2) in animals with non-immune system tumors, the lymphocytes of the animal can regulate the regression and metastasis of the tumor since the cellular immunotherapy The clinical field has rapidly expanded and people have studied lymphokine-activated killer (LAK) cells [2] and tumor infiltrating lymphatics (TI).